Investors focused on the Medical space have likely heard of GW Pharmaceuticals (GWPH), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
GW Pharmaceuticals is a member of our Medical group, which includes 850 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. GWPH is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GWPH's full-year earnings has moved 17.70% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that GWPH has returned about 69.71% since the start of the calendar year. At the same time, Medical stocks have gained an average of 10.03%. This means that GW Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Breaking things down more, GWPH is a member of the Medical - Products industry, which includes 77 individual companies and currently sits at #104 in the Zacks Industry Rank. Stocks in this group have gained about 12.59% so far this year, so GWPH is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track GWPH. The stock will be looking to continue its solid performance.
GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report
Original post
Zacks Investment Research